[The Japanese Transplant Registry Unified Management Program (TRUMP^®): current issues and the future]

The annual number of hematopoietic cell transplantation (HCT) in Japan exceeds 5,500 in recent years, and a steady increase in the HCT activity is observed globally. Transplant Registry Unification Management Program (TRUMP^®) data, the HCT outcome registry data (or real-world data) in Japan, played important roles in improving the therapeutic outcomes of HCT. Registry studies are actively performed by working groups, and >20 papers are published yearly using the TRUMP^® data. The development of shared scripts has contributed to improving the quality of registry data analyses. In January 2020, the TRUMP^® survey items were significantly revised according to the World Health Organization's disease classification revision and addition of new drug information, and >600 survey items were newly added. The quality control system for registry studies should be updated in response to this major change. The HCT registry is becoming HCT and cell therapy registry and is expected to expand the use of registry data, including the international collaborative research.